Cryo Cell International INC 10-Q quarterly reports

Cryo-Cell International reports a 2% revenue decrease for the quarter ended May 31, 2026, amidst ongoing arbitration with Duke University and NYSE listing concerns.

Cryo-Cell International, Inc. reported a decrease in revenue for the first quarter of fiscal year 2026, primarily due to lower public banking revenue and a slight dip in processing and storage fees, while SG&A expenses increased due to legal fees.

Cryo-Cell International reports a decrease in Q3 2025 revenue and net income, alongside escalating legal disputes with Duke University impacting future growth plans.

Cryo-Cell International, Inc. reported a significant decline in net income for the six months ended May 31, 2025, primarily impacted by increased expenses and the termination of its crucial license agreement with Duke University, which has halted key strategic growth initiatives.

Cryo-Cell International's Q1 2025 revenue increased slightly, but the company faces ongoing legal challenges and uncertainties regarding its Duke University license agreement.

Cryo-Cell International has filed an amendment to its quarterly report to update disclosures regarding an ongoing legal proceeding.

Cryo-Cell International's Q3 2024 results show a slight revenue increase, alongside strategic adjustments and ongoing legal proceedings.

Cryo-Cell International's latest 10-Q filing reveals a mix of revenue growth and strategic shifts, including the formation of a new subsidiary and ongoing clinical trial efforts.

Cryo-Cell International's first quarter results show a slight increase in revenue and a strategic focus on expanding its facilities and advancing clinical trials.